j.iyer

TL2 Moderator · Essen

Contributes reviews on supplier material. Based in Essen.

Joined 12 July 2025 · last posted 10d

93Posts here

0Topics

1Solutions

150Likes received

183Likes given

17Badges

52Days visited

445Posts read

Recent activity

Full stream

What to bring: records that a clinician can actually use Replied, post #6 · Clinical › Prescriber conversations · 18 Jul 2026 · 1 like I read post #4 twice before replying, because I had assumed the opposite. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so…
Reading order for a first week here, and what to skip until later — what changed since Replied, post #41 · Start Here › Welcome · 14 Jul 2026 · 19 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
Second pass at: When your prescriber and the evidence disagree Replied, post #49 · Clinical › Prescriber conversations · 12 Jul 2026 · 0 likes Asking about monitoring: understand what lab work will be done, how often, and what you will be monitored for. A plan is better than ad-hoc monitoring.
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #19 · Compounds › Repair & healing peptides · 8 Jul 2026 · 6 likes Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no…
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #31 · Compounds › Retatrutide · 2 Jul 2026 · 7 likes I read post #29 twice before replying, because I had assumed the opposite. Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises…
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #44 · Analytics › Home & field testing · 1 Jul 2026 · 4 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #93 · Analytics › HPLC & UHPLC · 1 Jul 2026 · 7 likes Picking up post #90: that is the part I would want checked first. Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary phase and…
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #34 · Analytics › Impurities & related substances · 29 Jun 2026 · 0 likes I read post #32 twice before replying, because I had assumed the opposite. Truncation products: fragments from incomplete synthesis or from degradation. They elute…
Does dual agonism explain the effect size, or is it dose? Replied, post #67 · Compounds › Tirzepatide · 28 Jun 2026 · 0 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #78 · Analytics › HPLC & UHPLC · 27 Jun 2026 · 14 likes Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing. The correction was fair and I had…
A site rotation scheme that is easy enough to actually follow Replied, post #96 · Practice › Administration · 23 Jun 2026 · 15 likes A site rotation scheme that actually works: abdomen, outer thigh, back of arm, outer hip. Rotate through them in order, move a minimum 2 cm between consecutive sites,…
Submitting a sample: the process end to end Replied, post #32 · Sourcing › Independent verification · 22 Jun 2026 · 3 likes This follows post #29 rather than contradicting it. Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still…